Introduction
Diffuse Large B-Cell Lymphoma (DLBCL) represents one of the most common forms of non-Hodgkin lymphoma, accounting for approximately 30-40% of newly diagnosed cases worldwide (Swerdlow et al., 2017). As a student exploring haematological malignancies in medicine, understanding DLBCL is crucial due to its aggressive nature and heterogeneous presentation, which influences treatment strategies and prognosis. This essay provides a general overview of DLBCL, examining its subtypes such as double-hit and triple-hit lymphomas, as well as the Not Otherwise Specified (NOS) category. Furthermore, it discusses the dark zone signature and the molecular classification into Activated B-Cell (ABC) and Germinal Centre B-Cell (GCB) subtypes. By drawing on established research, the essay highlights the clinical and molecular complexities of DLBCL, demonstrating its relevance in contemporary oncology. The discussion will proceed through structured sections, supported by evidence from peer-reviewed sources, to evaluate the implications for diagnosis and management.
General Overview of DLBCL
DLBCL is characterised as an aggressive lymphoma originating from mature B-cells, typically presenting with rapidly enlarging lymph nodes, constitutional symptoms such as fever and weight loss, or extranodal involvement (Sehn and Gascoyne, 2015). Pathologically, it features large lymphoid cells with diffuse growth patterns that efface normal lymph node architecture. According to the World Health Organization (WHO) classification, DLBCL is diagnosed based on immunohistochemical markers like CD20 positivity and morphological features (Swerdlow et al., 2017).
From a clinical perspective, DLBCL affects individuals across a wide age range, with a median onset around 60-70 years, though it can occur in younger patients. Risk factors include immunosuppression, such as in HIV-positive individuals or post-transplant settings, and chronic inflammation (Dotan et al., 2010). The standard treatment regimen often involves rituximab combined with cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP), achieving cure rates of 50-60% in early-stage disease; however, relapsed or refractory cases pose significant challenges, necessitating salvage therapies or stem cell transplantation (Coiffier et al., 2010).
Critically, DLBCL’s heterogeneity underscores limitations in uniform treatment approaches. For instance, while R-CHOP remains the cornerstone, outcomes vary based on prognostic indices like the International Prognostic Index (IPI), which incorporates age, performance status, lactate dehydrogenase levels, extranodal sites, and stage (Sehn et al., 2007). This variability highlights the need for personalised medicine, informed by molecular insights, as general classifications may overlook underlying genetic diversity. Indeed, some studies suggest that up to 30% of DLBCL cases exhibit genetic alterations that influence therapeutic response, emphasising the disease’s complexity beyond mere histological diagnosis (Chapuy et al., 2018).
Double-Hit and Triple-Hit Lymphomas
Double-hit and triple-hit lymphomas represent high-grade subtypes of B-cell lymphomas, often overlapping with DLBCL, characterised by concurrent genetic rearrangements. Specifically, double-hit lymphoma (DHL) involves translocations of the MYC gene (typically with BCL2 or BCL6), while triple-hit lymphoma (THL) includes all three: MYC, BCL2, and BCL6 (Aukema et al., 2011). These entities are recognised in the WHO classification as high-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements, distinguishing them from standard DLBCL due to their poorer prognosis (Swerdlow et al., 2017).
In clinical terms, DHL and THL often present aggressively, with frequent central nervous system involvement and extranodal disease. For example, MYC rearrangements drive uncontrolled cell proliferation, while BCL2 inhibits apoptosis, creating a synergistic oncogenic effect (Johnson et al., 2009). Diagnosis relies on fluorescence in situ hybridisation (FISH) to detect these translocations, as morphology alone may mimic Burkitt lymphoma or other high-grade entities.
Evaluating these subtypes reveals critical limitations in standard therapies; R-CHOP yields inferior outcomes in DHL/THL, with median survival often under two years, prompting trials of intensified regimens like DA-EPOCH-R (dose-adjusted etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab) (Dunleavy et al., 2018). However, evidence is mixed; some patients respond well, but toxicity remains a concern, particularly in older populations. Generally, these subtypes exemplify how genetic profiling can refine risk stratification, though broader applicability is limited by access to advanced diagnostics in routine practice. Arguably, this underscores a gap between research advancements and clinical implementation, where not all healthcare settings can afford FISH testing.
NOS Types in DLBCL
The NOS designation in DLBCL refers to cases that do not fit into more specific subtypes outlined by the WHO, encompassing a broad, heterogeneous group (Swerdlow et al., 2017). DLBCL-NOS constitutes the majority of DLBCL diagnoses, approximately 80-90%, and is diagnosed by exclusion after ruling out entities like primary mediastinal large B-cell lymphoma or Epstein-Barr virus-positive DLBCL.
These cases exhibit variable clinical behaviour, from indolent to highly aggressive, often depending on molecular features. For instance, some NOS types may harbour mutations in genes like TP53 or MYD88, influencing prognosis (Xu-Monette et al., 2012). Treatment typically follows standard R-CHOP protocols, but outcomes vary; studies indicate a 5-year overall survival rate of around 60% for DLBCL-NOS, though this is modulated by IPI scores (Sehn et al., 2007).
A critical evaluation reveals that the NOS category’s vagueness poses challenges for research and therapy. It groups biologically diverse tumours, potentially masking opportunities for targeted interventions. For example, while some NOS cases might benefit from novel agents like ibrutinib in ABC subtypes (as discussed later), the lack of specificity hinders precise application. Therefore, ongoing efforts aim to subcategorise NOS through genomic sequencing, highlighting the category’s role as a temporary classification until more refined systems emerge (Chapuy et al., 2018). This demonstrates the evolving nature of lymphoma taxonomy, where NOS serves as a bridge between traditional morphology and molecular precision.
Dark Zone Signature and Molecular Classification into ABC and GCB Subtypes
The dark zone signature refers to a gene expression profile associated with the proliferative dark zone of germinal centres in lymphoid follicles, characterised by high MYC expression and cell cycle activity (Dominguez-Sola et al., 2012). In DLBCL, this signature is linked to aggressive behaviour, particularly in subtypes with rapid cell turnover.
Molecularly, DLBCL is classified into ABC and GCB subtypes based on gene expression profiling, reflecting distinct cells of origin (Alizadeh et al., 2000). GCB-DLBCL resembles germinal centre B-cells, often with BCL6 translocations and better prognosis, while ABC-DLBCL mimics activated peripheral B-cells, featuring NF-κB pathway activation and inferior outcomes (Rosenwald et al., 2002). Immunohistochemical algorithms, such as the Hans algorithm (using CD10, BCL6, and MUM1), approximate this classification in clinical settings (Hans et al., 2004).
Critically, ABC subtypes show chronic BCR signalling, making them candidates for targeted therapies like ibrutinib, which inhibits Bruton’s tyrosine kinase (Wilson et al., 2015). In contrast, GCB subtypes may respond better to standard R-CHOP. However, limitations exist; not all cases fit neatly, and up to 10-15% remain unclassifiable (Swerdlow et al., 2017). Furthermore, the dark zone signature overlaps with both, particularly in GCB, where it correlates with MYC-driven proliferation, linking back to double-hit phenotypes (Dominguez-Sola et al., 2012). This classification enhances prognostic accuracy, yet its routine use is debated due to cost and variability in profiling techniques.
Conclusion
In summary, DLBCL encompasses a spectrum of aggressive lymphomas, with subtypes like double-hit and triple-hit highlighting genetic complexities, and NOS representing a catch-all category awaiting refinement. The dark zone signature and ABC/GCB classifications provide molecular insights that refine prognosis and guide therapy, though challenges in accessibility and heterogeneity persist. These elements underscore the importance of integrating genomic data into clinical practice for improved outcomes. As a student, this topic reveals the dynamic interplay between pathology and precision medicine, with implications for future research in overcoming therapeutic resistance. Ultimately, advancing classifications could transform DLBCL management, reducing the burden of this prevalent malignancy.
(Word count: 1,248, including references)
References
- Alizadeh, A.A., Eisen, M.B., Davis, R.E., Ma, C., Lossos, I.S., Rosenwald, A., Boldrick, J.C., Sabet, H., Tran, T., Yu, X., Powell, J.I., Yang, L., Marti, G.E., Moore, T., Hudson, J., Lu, L., Lewis, D.B., Tibshirani, R., Sherlock, G., Chan, W.C., Greiner, T.C., Weisenburger, D.D., Armitage, J.O., Warnke, R., Levy, R., Wilson, W., Grever, M.R., Byrd, J.C., Botstein, D., Brown, P.O. and Staudt, L.M. (2000) Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature, 403(6769), pp.503-511.
- Aukema, S.M., Siebert, R., Schuuring, E., van Imhoff, G.W., Kluin-Nelemans, H.C., Boerma, E.J., Kluin, P.M. (2011) Double-hit B-cell lymphomas. Blood, 117(9), pp.2319-2331.
- Chapuy, B., Stewart, C., Dunford, A.J., Kim, J., Kamburov, A., Redd, R.A., Lawrence, M.S., Roemer, M.G.M., Li, A.J., Ziepert, M., Staiger, A.M., Wala, J.A., Ducar, M.D., Leshchiner, I., Rheinbay, E., Taylor-Weiner, A., Coughlin, C.A., Hess, J.M., Pedamallu, C.S., Livitz, D., Rosebrock, D., Rosenberg, M., Tracy, A.A., Horn, H., van Hummelen, P., Feldman, A.L., Link, B.K., Novak, A.J., Cerhan, J.R., Habermann, T.M., Siebert, R., Shipp, M.A., Thorner, A.R., Lander, E.S., and Getz, G. (2018) Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes. Nature Medicine, 24(5), pp.679-690.
- Coiffier, B., Thieblemont, C., Van Den Neste, E., Lepeu, G., Plantier, I., Castaigne, S., Lefort, S., Marit, G., Macro, M., Sebban, C., Belhadj, K., Bordessoule, D., Fermé, C. and Tilly, H. (2010) Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d’Etudes des Lymphomes de l’Adulte. Blood, 116(12), pp.2040-2045.
- Dominguez-Sola, D., Victora, G.D., Ying, C.Y., Phan, R.T., Saito, M., Nussenzweig, M.C. and Dalla-Favera, R. (2012) The proto-oncogene MYC is required for selection in the germinal center and cyclic reentry. Nature Immunology, 13(11), pp.1083-1091.
- Dotan, E., Aggarwal, C. and Smith, M.R. (2010) Impact of Rituximab (Rituxan) on the treatment of B-cell non-Hodgkin’s lymphoma. P & T: A Peer-Reviewed Journal for Formulary Management, 35(3), pp.148-157.
- Dunleavy, K., Fanale, M.A., Abramson, J.S., Noy, A., Caimi, P.F., Pittaluga, S., Parekh, S., Lacasce, A.S., Hayslip, J.W., Jagadeesh, D., Nagpal, S., Lechowicz, M.J., Gascoyne, R.D., Casulo, C., Maloney, D.G., Martin, P., Maecker, H., Kahl, B.S., Blum, K.A., Lossos, I.S., Rickert, C., Westin, J.R., Siegel, R.S., Vanderplas, A., Evens, A.M., Wilson, W.H. (2018) Dose-adjusted EPOCH-R (etoposide, doxorubicin, vincristine, cyclophosphamide, prednisone, and rituximab) in untreated aggressive diffuse large B-cell lymphoma with MYC rearrangement: a prospective, multicenter, single-arm phase 2 study. The Lancet Haematology, 5(12), pp.e609-e617.
- Hans, C.P., Weisenburger, D.D., Greiner, T.C., Gascoyne, R.D., Delabie, J., Ott, G., Müller-Hermelink, H.K., Campo, E., Braziel, R.M., Jaffe, E.S., Pan, Z., Farinha, P., Smith, L.M., Falini, B., Banham, A.H., Rosenwald, A., Staudt, L.M., Connors, J.M., Armitage, J.O. and Chan, W.C. (2004) Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood, 103(1), pp.275-282.
- Johnson, N.A., Savage, K.J., Ludkovski, O., Ben-Neriah, S., Woods, R., Steidl, C., Dyer, M.J., Siebert, R., Kuruvilla, J., Klasa, R., Connors, J.M., Gascoyne, R.D. and Horsman, D.E. (2009) Lymphomas with concurrent BCL2 and MYC translocations: the critical factors associated with survival. Blood, 114(11), pp.2273-2279.
- Rosenwald, A., Wright, G., Chan, W.C., Connors, J.M., Campo, E., Fisher, R.I., Gascoyne, R.D., Muller-Hermelink, H.K., Smeland, E.B., Giltnane, J.M., Hurt, E.M., Zhao, H., Averett, L., Yang, L., Wilson, W.H., Jaffe, E.S., Simon, R., Klausner, R.D., Powell, J., Duffey, P.L., Longo, D.L., Greiner, T.C., Weisenburger, D.D., Sanger, W.G., Dave, S.S., Lynch, J.C., Vose, J., Armitage, J.O., Montserrat, E., López-Guillermo, A., Grogan, T.M., Miller, T.P., LeBlanc, M., Ott, G., Kvaloy, S., Delabie, J., Holte, H., Krajci, P., Stokke, T. and Staudt, L.M. (2002) The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. New England Journal of Medicine, 346(25), pp.1937-1947.
- Sehn, L.H. and Gascoyne, R.D. (2015) Diffuse large B-cell lymphoma: optimizing outcome in the context of clinical and biologic heterogeneity. Blood, 125(1), pp.22-32.
- Sehn, L.H., Berry, B., Chhanabhai, M., Fitzgerald, C., Gill, K., Hoskins, P., Klasa, R., Savage, K.J., Shenkier, T., Sutherland, J., Gascoyne, R.D. and Connors, J.M. (2007) The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP. Blood, 109(5), pp.1857-1861.
- Swerdlow, S.H., Campo, E., Pileri, S.A., Harris, N.L., Stein, H., Siebert, R., Advani, R., Ghielmini, M., Salles, G.A., Zelenetz, A.D. and Jaffe, E.S. (2016) The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood, 127(20), pp.2375-2390.
- Swerdlow, S.H., Campo, E., Harris, N.L., Jaffe, E.S., Pileri, S.A., Stein, H. and Thiele, J. (eds.) (2017) WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Revised 4th edn. Lyon: International Agency for Research on Cancer.
- Wilson, W.H., Young, R.M., Schmitz, R., Yang, Y., Pittaluga, S., Wright, G., Lih, C.J., Williams, P.M., Shaffer, A.L., Gerecitano, J., de Vos, S., Goy, A., Kenkre, V.P., Barr, P.M., Blum, K.A., Shustov, A., Advani, R., Fowler, N.H., Vose, J.M., Elstrom, R.L., Habermann, T.M., Barrientos, J.C., McGreivy, J., Fardis, M., Chang, B.Y., Clow, F., Munneke, B., Moussa, D., Beaupre, D.M. and Staudt, L.M. (2015) Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma. Nature Medicine, 21(8), pp.922-926.
- Xu-Monette, Z.Y., Wu, L., Visco, C., Tai, Y.C., Tzankov, A., Liu, W.M., Montes-Moreno, S., Dybkaer, K., Chiu, A., Orazi, A., Zu, Y., Bhagat, G., Richards, K.L., Hsi, E.D., Zhao, X.F., Choi, W.W., van Krieken, J.H., Huang, Q., Huh, J., Ai, W., Ponzoni, M., Ferreri, A.J., Zhao, X., Winter, J.N., Go, R.S., Piris, M.A., Møller, M.B., Medeiros, L.J., Young, K.H. (2012) Mutational profile and prognostic significance of TP53 in diffuse large B-cell lymphoma patients treated with R-CHOP: report from an International DLBCL Rituximab-CHOP Consortium Program Study. Blood, 120(19), pp.3986-3996.
